TARDBP and amyotrophic lateral sclerosis: Further work will be needed to assess the specificity and sensitivity of cryptic peptides as biomarkers, but, taken together, these discoveries are encouraging steps towards facilitating earlier diagnosis of ALS, and also providing a way of measuring target engagement in clinical trials for new therapies aimed at restoring TDP-43 function.